William M. Garrett - Concepedia

Author

William M. Garrett

Incyte (United States)

Also Known As

W. Garrett, William Garrett, William M Garrett, William M. Garrett, william garrett

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Incyte (United States)The University of Texas MD Anderson Cancer Center University of Florence University of Bergamo Policlinico San Matteo Fondazione

About

William M. Garrett is an author at Incyte (United States) specializing in pharmacotherapy, immunology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	100
2	Immunology	3	3	100
3	Pharmacology	3	3	100
4	Health Sciences	2	2	67
5	Classical Hematology	1	1	16

William M. Garrett

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer, New England Journal of Medicine	2015	851
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed Herbert I. Hurwitz, Nikhil Uppal, Stephanie A. Wagner, Journal of Clinical Oncology	2015	279
Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU) Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Blood	2010	61
A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC). Herbert I. Hurwitz, Nikhil Uppal, Stephanie A. Wagner, Journal of Clinical Oncology ImmunologyPharmacotherapyMetastatic Pancreatic CancerMpc RefractoryCancer Infl	2014	51
A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea. Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Blood	2009	48
Clinical Benefit of INCB7839, a Potent and Selective Inhibitor of ADAM10 and ADAM17, in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer Patients. Steven Friedman, Richard Levy, William M. Garrett, Cancer Research Breast OncologyImmunologyPharmacotherapyTumor BiologyHer2 Cleavage	2009	33
Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial Srđan Verstovšek, Jean‐Jacques Kiladjian, Martin Grießhammer, Journal of Clinical Oncology ImmunohematologyImmunologyPharmacotherapyJak InhibitorMyeloid Neoplasia	2014	16

Page 1